Top 9 Healthcare Stocks to Buy According to Billionaire David Einhorn

5. Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Greenlight Capital’s Equity Stakes: $10.33 Million

Number of Hedge Fund Holders: 72

Teva Pharmaceutical Industries Limited (NYSE:TEVA) develops, manufactures, and distributes generic and other medicines and biopharmaceutical products. The company specializes in providing affordable and accessible medicines to patients worldwide. It’s long-term prospects received a significant boost late last year after results from a clinical study of its candidate drug for ulcerative colitis and Crohn’s disease, Dukakitug, met primary goals.

Following the positive results, Teva Pharmaceutical Industries Limited (NYSE:TEVA) is poised to lead the commercialization of the product in Europe, Israel and other countries. The medication may be used for purposes other than inflammatory bowel disease. Duvakitug’s successful Phase 2b research results have paved the way for more clinical trials.

Despite the anticipated sharp drop in sales from its generic version of Revlimid in 2026, analysts at Piper Sandler have emphasized Duvakitug’s potential to support Teva’s expansion. The research firm has expressed its confidence in Teva’s capacity to increase its market value due to the company’s strategic efforts and the potential of its therapeutic pipeline.

Amid the positive clinical trial results, Teva Pharmaceutical Industries Limited (NYSE:TEVA) delivered solid Q4 2024 results, which were helped by double-digit sales gains of its branded drugs for migraines, Huntington’s disease, and schizophrenia. Revenue in the quarter totalled $4.2 billion as earnings per share came in at 71 cents a share. Teva expects 2025 revenue to average between $16.8 billion and $17.4 billion with diluted earnings per share of between $2.35 and $2.65.